Trials / Completed
CompletedNCT02999373
Autologous Cord Blood Mononuclear Cells for Bronchopulmonary Dysplasia in Very Preterm Neonates
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Guangdong Women and Children Hospital · Academic / Other
- Sex
- All
- Age
- 0 Weeks – 32 Weeks
- Healthy volunteers
- Not accepted
Summary
Rationale: Pre-clinical animal studies provide robust evidence regarding the beneficial effect of cord blood-derived mononuclear cells (MNCs) for experimental bronchopulmonary dysplasia (BPD). This single-center, non-randomized, controlled, blinded trial assessed the effect of a single intravenous infusion of autologous cord blood MNCs (ACBMNCs) in preventing BPD in very preterm neonates, a high-risk population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Autologous Umbilical Cord Blood Mononuclear Cells Therapy | Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
- First posted
- 2016-12-21
- Last updated
- 2021-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02999373. Inclusion in this directory is not an endorsement.